Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

Correction to: Arthritis Res Ther

https://doi.org/10.1186/s13075-019-1880-4

Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process. The original article [1] has been corrected.

In Fig. 1b, the heading should read: Adjusted survival due to lack of effectiveness

Fig. 1.

Drug survival rates due to lack of effectiveness in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

In Fig. 2b, the heading should read: Adjusted survival due to toxic adverse events

Fig. 2.

Drug survival rates due to toxic adverse events in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

In addition, the authors would like to update the legends of Figure 1, 2, 3 and 4 to the following:

Fig. 1 Drug survival rates due to lack of effectiveness in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 2 Drug survival rates due to toxic adverse events in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 3 Drug survival rates due to remission in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 4 Overall drug survival rates (excluding non-toxic reasons and remission) in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

The publishers apologise for the errors. The corrected figures are given below: